Price redetermination for Omeprazole oral suspension (September and October 2023)
Following representations made by Community Pharmacy England, DHSC agreed to the following redeterminations for the September and October 2023 Drug Tariffs:
- the addition of licensed Omeprazole 1mg/1ml oral suspension sugar free (75ml) to Category C based on Rosemont Pharmaceuticals Ltd
- the deletion of unlicensed Omeprazole 5mg/5ml oral suspension from Part VIIIB
Payment for September and October’s prescriptions will reflect the above retrospective determination and hence will not be as per the published Drug Tariff.
A licensed version of Omeprazole 1mg/1ml oral suspension sugar free (75ml) with a list price of £111.10 was recently launched in the market by Rosemont Pharmaceuticals Ltd. However, there is currently a listing for an unlicensed Omeprazole 5mg/5ml oral suspension in Part VIIIB of the Drug Tariff. Therefore, according to Drug Tariff rules, any generically written prescriptions for Omeprazole 1mg/1ml (or 5mg/5ml) oral suspension sugar free would be reimbursed according to the price listed in Part VIIIB of the September and October Drug Tariff (£11.10 per 100ml and then 8p per every additional ml).
This led to concerns from pharmacy owners regarding the reimbursement risks for supplying the licensed product against a generically written prescription for Omeprazole 1mg/1ml (or 5mg/5ml) oral suspension sugar free. To reflect the availability of licensed product from September 2023, Community Pharmacy England made representations to the Department of Health and Social Care seeking an adjustment to the reimbursement price for September and October prescriptions.